Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086880 | 0.99 | MC4R (0.71) | MC4RKDM4ETDP1CCR5 | |
| SCHEMBL3095821 | 0.95 | MC4R (0.70) | MC4RKDM4ETDP1CCR5 | |
| SCHEMBL3089626 | 0.93 | MC4R (0.63) | MC4R | |
| SCHEMBL3082692 | 0.89 | MC4R (0.56) | MC4R | |
| SCHEMBL3095645 | 0.88 | MC4R (0.68) | MC4R | |
| SCHEMBL3095891 | 0.83 | MC4R (0.69) | MC4R | |
| SCHEMBL3089406 | 0.83 | MC4R (0.49) | MC4RKDM4ETDP1 | |
| SCHEMBL3086877 | 0.82 | MC4R (0.50) | MC4RKDM4ETDP1CCR5 | |
| SCHEMBL3090273 | 0.82 | MC4R (1.00) | MC4R | |
| SCHEMBL3082228 | 0.82 | MC4R (0.75) | MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1590338-B1 | MODULATORS OF MELANOCORTIN RECEPTOR | ORE PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1590338-A2 | MODULATORS OF MELANOCORTIN RECEPTOR | Gene Logic Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040147746-A1 | Modulators of melanocortin receptor | MILLENNIUM PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004050610-A2 | MODULATORS OF MELANOCORTIN RECEPTOR | GENE LOGIC INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293498-A1 | Modulators of melanocortin receptor | MC4R, MC1R, MC5R | MC4R 1/4885KDM4E 1878/4885TDP1 4865/4885 |
| US-20040147746-A1 | Modulators of melanocortin receptor | MC1R, MC3R, MC5R | MC4R 4/4885KDM4E 2340/4885TDP1 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.